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Published studies have added to general knowledge of the best candidates for adju vant chemotherapy after rC but physi cians and patients have few tools to help them translate this body of knowledge into individualized, evidencebased recom mendations. Patients with lymph node involvement or metastatic disease are usually counseled in favor of adjuvant chemotherapy as it has been suggested to improve diseasefree survival in this population. However, the existing data is underpowered and insufficient for base clinical decision making, which leaves both the practitioner and patient in a quandary when discussing clinical outcomes after rC and the potential benefits and harms of adjuvant therapy. multivariable predic tion tools, such as the iBCnC nomogram, repre sent the most accurate and discrimi nating methods of predicting outcomes in patients with bladder cancer. equipped with accurate prediction and a personalized clinical decision, patients are more likely to be confident in their treatment deci sions and less likely to experience regret in the future.
the integration of novel biomarkers that are associated with the biological behavior of bladder cancer and data derived from imaging modalities might further improve the accuracy of nomogram predictions. 8 For example, assessment of biomarkers for cellcycle regulation (p53, prB, p21, and p27), cell proliferation (Ki67), and apop tosis (Bcl2, caspase3, and survivin) in rC specimens has been shown to improve our current prediction of bladder cancer recur rence and survival by a prognostically and clinically significant margin. [8] [9] [10] indeed, the emergence of new therapeutic approaches for bladder cancer cannot flourish without a set of biomarkers to serve as prognosti cators, therapeutic targets, and surrogate end points. integration of biomarkers with standard clinical and pathologic features in predic tive tools such as nomograms holds the promise of improving outcomes for patients with bladder cancer.
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Utility of the Riskindicator model in screening
Stacy Loeb and William J. Catalona
use of a multivariable 'riskindicator' model might increase the accuracy of screening for clinically significant prostate cancer. Such models, in conjunction with novel biomarkers, hold promise for improving the specificity of screening, and could help to reduce the number of unnecessary biopsies performed in this setting.
Key issues in prostate cancer screening include the lack of specificity of Psa testing, which leads to unnecessary biopsies, and the detection and treatment of a proportion of tumors that will never present clinically. thus, much research effort is directed at improving the accuracy of prostate cancer screening. in one such study, roobol and colleagues 1 describe the use of a multi variable 'riskindicator' model in conjunc tion with the serum Psa level to improve the prediction of prostate cancer risk and reduce the number of unnecessary biop sies in a subset of men from the european randomized study of screening for Prostate Cancer (ersPC). they conclude that the riskindicator model might be beneficial in the primary and repeat biopsy settings to increase the specificity of screening for prostate cancer.
the riskindicator is a predictive tool that was originally developed in a cohort of 6,288 men from the rotterdam section of the ersPC. it has been examined in differ ent formats (logistic regression model and graphical device), 2, 3 and is now avail able online for public use (Figure 1) . 4 the riskindicator model includes the follow ing variables: serum Psa level, digital rectal examination results, and transrectal ultrasonography (trus) findings (prostate volume and presence of hypoechoic lesion).
in the current study, the investigators first evaluated the ability of the riskindicator model to predict the results of initial prostate biopsy in 1,850 men from the rotterdam section of the ersPC. they also tested an expanded model that incorporated prior biopsy history among 1,201 men who underwent repeat screening 4 years later. Finally, they estimated the relative propor tion of 'indolent' and 'important' cancers that would have been missed using these riskindicator models.
at the initial biopsy, which was triggered by a Psa threshold of 3 ng/ml, prostate cancer was detected in 541 men, represent ing a positive predictive value of 29%. using the riskindicator model, the mean predicted probability of prostate cancer was 43% nature reviews | urology volume 7 | aPril 2010 | 185
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(range 3-99%) in men with a positive biopsy, compared to 20% (range 1-88%) for those with a negative biopsy. on receiver operat ing characteristic analysis, the area under the curve (auC) for the model was 0.77.
at the repeat screening, 1,201 men underwent biopsy, of which 568 (47%) had a prior negative biopsy at the first screening. overall, 225 (19%) cancers were detected. the riskindicator algorithm gave a mean predicted probability of prostate cancer of 26% (range 4-74%) in men with a posi tive biopsy, versus 17% (range 2-62%) for those with a negative biopsy. in this group, the riskindicator had an auC of 0.71 for the prediction of prostate cancer on repeat screening. the researchers then investigated the effect of different riskindicator cutoff points on prostate cancer detection. if a riskindicator predicted probability of ≥12.5% was taken as the indication for biopsy, the model would have missed 73 (14%) and 37 (16%) cancers at the initial and repeat screenings, respec tively. However, the authors estimated that 70% and 81% of these tumors met their criteria for 'potentially indolent' features.
limitations of this study include the use of a limited sextant biopsy scheme, the over lapping wide ranges of predicted probabilities of prostate cancer using the riskindicator, and the criteria used to define indolent disease. the riskindicator defines indolent cancers as clinical stage ≤t2, Psa ≤20 ng/ml, primary and second ary Gleason grade ≤3, ≤50% positive cores, <20 mm total cancer in biopsy cores, and benign tissue in all cores ≥40 mm. thus, a patient with a serum Psa level of 19 ng/ml and clinical stage t2b lesion with a positive core in each lobe containing 9 mm cancer (D' amico intermediaterisk disease 5 ) could potentially be considered to have indolent prostate cancer by the authors' criteria. the riskindicator might miss a greater pro portion of potentially important tumors if morestringent criteria for indolent cancer were used.
another important issue with the riskindicator is the inclusion of multiple parameters from trus, which is typically performed after the decision has been made to proceed with prostate biopsy, and the fact that virtually all patients have hypoecho genic regions on trus. thus, this algorithm might not be pragmatic in the initial screen ing setting. owing to the lack of consensus over the indications for and timing of repeat biopsy, the riskindicator might be a more helpful predictive tool at this stage, using trus findings from the original biopsy.
Finally, the riskindicator models used in this study did not incorporate other impor tant variables such as Psa velocity. not only has this parameter been shown to enhance the specificity of screening for clinically signifi cant prostate cancer, 6 but a Psa velo city greater than 0.35 ng/ml/year predicts an increased risk of fatal prostate cancer more than a decade before diagnosis. 7 Despite these limitations, this study will be an important contribution in the ongoing effort to improve prostate cancer screen ing protocols, if validated in independent, external datasets. as predictive tools can perform differently in populations with differ ent underlying features, 8 it will be critical to test the riskindicator in more diverse patient populations. once further validated, the benefits of the riskindicator are that it uses straightforward predictors, and that it is available online, which makes it readily applicable in the clinic.
Prostate biopsy is an invasive procedure with the potential for serious infectious and noninfectious complications. moreover, the identification through conventional screening of tumors that will remain indo lent leads to unnecessary overtreatment for many patients. as suggested by roobol and colleagues, 1 the incorporation of multiple predictors into a riskassessment tool, such as the riskindicator, along with the identi fication of new biomarkers, might help to improve the specificity of prostate cancer screening programs and reduce the frequency of unnecessary biopsies in the future. Figure 1 | The online Riskindicator. This example predicts the risk of prostate cancer in a previously screened patient with a negative prior biopsy (positive TRUs, negative DRe, prostate volume 30 ml, PsA 3.5 ng/ml). The chance of the patient having a positive biopsy is 21%. Colors: green, TRUs; pink, DRe; blue, prostate volume (ml); red, PsA (ng/ml). image obtained from swOP Prostate Cancer Research Foundation (www.prostatecancer-riskcalculator.com). Abbreviations: DRe, digital rectal examination; TRUs, transrectal ultrasonography.
